GO
Loading...

Pfizer and Astrazeneca have 'very little growth': Pro

Tuesday, 6 May 2014 | 2:15 AM ET

Navid Malik, head of life sciences research at Cenkos Securities, says if Pfizer is successful in acquiring Astrazeneca, it could look at some cost-cutting measures.